Prodrugs for Improved Drug Delivery: The Journey and the Conversion

A prodrug begins as a modified precursor, not as a drug that has simply found a better route. Skinjo sketches its journey in three panels: the precursor, the barrier, and the active drug. The spaces between the panels matter as much as the forms themselves.

First, the modification can change a property that makes delivery difficult. A compound may dissolve poorly, struggle to pass through a membrane, or be lost before enough of it reaches the relevant tissue. Designing a precursor with different properties is one way to address such obstacles. The review *Prodrugs for Improved Drug Delivery: Lessons Learned from Recently Developed and Marketed Products* examines that strategy through developed and marketed examples; it does not make every proposed modification a proven solution.

Next comes the barrier. Changing how a precursor travels can improve an aspect of delivery, but passage depends on the particular compound, route, and biological setting. A useful alteration for one obstacle does not imply effortless passage through all the others.

Finally, the precursor must be converted into the active drug. That conversion is a separate question from whether the precursor got through a barrier: where, when, and how much conversion occurs all affect the result. A chemical modification is not evidence that activation happens exclusively at the intended destination. The clearest reading of the journey is therefore a design aim, not a promise of perfect targeting: assess the trip and the transformation on their own terms.